TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

Abstract Tumors that lack pre-existing immune infiltration respond poorly to T cell checkpoint blockade immunotherapy. These cancers often surround themselves with high densities of suppressive myeloid stroma while excluding immunostimulatory dendritic cells. Tumor-resident myeloid cells and selecte...

Full description

Bibliographic Details
Main Authors: Matthew J. Reilley, Brittany Morrow, Casey R. Ager, Arthur Liu, David S. Hong, Michael A. Curran
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
TLR9
CTLA-4
PD-1
Immunotherapy
MGN1703
Online Access:http://link.springer.com/article/10.1186/s40425-019-0811-x

Internet

http://link.springer.com/article/10.1186/s40425-019-0811-x

Similar Items